This MedLibrary.org supplementary page on Tissue plasminogen Activator is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
|
Plasminogen activator, tissue
|
||||||||||||||
 |
||||||||||||||
| PDB rendering based on 1a5h. | ||||||||||||||
| Available structures: 1a5h, 1bda, 1pk2, 1pml, 1rtf, 1tpg, 1tpk, 1tpm, 1tpn | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbols | PLAT; DKFZp686I03148; T-PA; TPA | |||||||||||||
| External IDs | OMIM: 173370 MGI: 97610 HomoloGene: 717 | |||||||||||||
|
||||||||||||||
| RNA expression pattern | ||||||||||||||
|
|
||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 5327 | 18791 | ||||||||||||
| Ensembl | ENSG00000104368 | ENSMUSG00000031538 | ||||||||||||
| Uniprot | P00750 | Q6P7U0 | ||||||||||||
| Refseq | NM_000930 (mRNA) NP_000921 (protein) |
NM_008872 (mRNA) NP_032898 (protein) |
||||||||||||
| Location | Chr 8: 42.15 - 42.18 Mb | Chr 8: 24.22 - 24.25 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
Tissue plasminogen activator (abbreviated tPA or PLAT) is a serine protease normally found on the surface of endothelial cells of veins, capillaries, the pulmonary artery, heart, and uterus, and is secreted after vascular injury. It converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Plasminogen is synthesized as a single chain, which is cleaved by tPA into the two chain disulfide linked plasmin.
Contents |
Function
This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism.
Gene
Alternative splicing of the tPA gene, tPA, produces three transcripts.
Clinical applications
Recombinant tPA is used in diseases that feature blood clots, such as pulmonary embolism, myocardial infarction and stroke. To be effective, tPA must be administered within the first three hours of the event to be given intravenously, or within six hours to be administered through an arterial catheter directly to the site of occlusion. The guideline in Ontario, Canada hospitals for ischemic strokes is that tPA must be given within 3 hours of the onset of symptoms. Because of this, only about 3% of patients qualify for this treatment. tPA appears to show benefit not only for large artery occlusions but also for lacunar strokes. Since tPA dissolves blood clots, there is risk of hemorrhage with its use.
Recently tPA has been used to dissolve thrombi associated with ischemic strokes and brain injury.
In addition, people with frostbite that were treated with tPA had fewer amputations than those that were not[1].
Further reading
- Rijken DC (1988). "Relationships between structure and function of tissue-type plasminogen activator". Klin. Wochenschr. 66 Suppl 12: 33–9. PMID 3126346.
- Bode W, Renatus M (1998). "Tissue-type plasminogen activator: variants and crystal/solution structures demarcate structural determinants of function". Curr. Opin. Struct. Biol. 7 (6): 865–72. PMID 9434908.
- Collen D, Billiau A, Edy J, De Somer P., Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta. 1977 Sep 29;499(2):194-201
- Anglés-Cano E, Rojas G (2003). "Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site". Biol. Chem. 383 (1): 93–9. PMID 11928826.
- Ny T, Wahlberg P, Brändström IJ (2003). "Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems". Mol. Cell. Endocrinol. 187 (1-2): 29–38. PMID 11988309.
- Teesalu T, Kulla A, Asser T, et al. (2002). "Tissue plasminogen activator as a key effector in neurobiology and neuropathology". Biochem. Soc. Trans. 30 (2): 183–9. doi:10.1042/ (inactive 2008-06-21). PMID 12023848.
- Pang PT, Lu B (2005). "Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF". Ageing Res. Rev. 3 (4): 407–30. doi:. PMID 15541709.
- Sheehan JJ, Tsirka SE (2005). "Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review". Glia 50 (4): 340–50. doi:. PMID 15846799.
References
- ^ "Archives of Surgery". Reduction of the Incidence of Amputation in Frostbite Injury With Thrombolytic Therapy, Bruen et al., 2007;142:546-553.
See also
External links
- http://www.americanheart.org/presenter.jhtml?identifier=4751
- Widening the Window : Strategies to buy time in treating ischemic stroke - Scientific American Magazine (August 2005)
|
|||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
 |
This hydrolase article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 23 August 2008, at 09:49.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Tissue plasminogen Activator".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.